This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
BIND and Affilogic are collaborating to develop compounds using BIND's ACCURINS and Affilogic's Nanofitins.
ACCURINS are proprietary polymeric nanoparticles that are engineered to target specific cells and tissues in the body at sites of disease.
Nanofitins are small affinity proteins that can be easily conjugated to other moieties (small molecule, biologics, nanoparticles) by genetic fusion or standard chemistry (regioselective conjugation).
BIND and Affilogic
In May 2016, BIND Therapeutics announced a research collaboration with Affilogic. Under terms of the collaboration, BIND will utilize Nanofitins as targeting ligand components for ACCURINS designed to bind immuno-oncology targets. Upon achievement of proof-of-concept, BIND anticipates expanding the collaboration to develop ACCURINS that incorporate unique combinations of immuno-oncology targeting ligands and new classes of payloads, including oligonucleotides and molecularly targeted therapies.
BIND and Pfizer
In July 2016, BIND Therapeutics announced it has filed a motion for court approval of a stalking horse asset purchase agreement bid from Pfizer for the purchase of the majority of BIND's assets. The agreement is the initial stalking horse bid under Section 363 of the U.S. Bankruptcy Code, to be followed by an orderly auction process as established by the U.S. Bankruptcy Court. Under terms of the agreement, Pfizer has agreed to...See full deal structure in Biomedtracker
Additional information available to subscribers only: